Wyeth, Baxter Recombinant Factor VIII Licenses Subject Of FTC Inquiry
Executive Summary
Wyeth and Baxter have been contacted by the Federal Trade Commission to provide documentation regarding licensing agreements for their recombinant factor VIII hemophilia A products